Vident Investment Advisory, LLC Ascendis Pharma A/S Put Options Transaction History
Vident Investment Advisory, LLC
- $0
- Q3 2023
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ASND
# of Institutions
236Shares Held
60.2MCall Options Held
80.3KPut Options Held
216K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.67 Billion22.55% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.53MShares$910 Million3.52% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.1MShares$840 Million10.24% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.45MShares$733 Million0.98% of portfolio
-
Janus Henderson Group PLC London, X04.38MShares$721 Million0.32% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $9.19B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...